Natural history of multiple sclerosis.
作者信息
Ebers G C
机构信息
University Department of Clinical Neurology, Radcliffe Infirmary, Oxford, UK.
出版信息
J Neurol Neurosurg Psychiatry. 2001 Dec;71 Suppl 2(Suppl 2):ii16-9. doi: 10.1136/jnnp.71.suppl_2.ii16.
Abstract
摘要
相似文献
1
Natural history of multiple sclerosis.多发性硬化症的自然病史。
J Neurol Neurosurg Psychiatry. 2001 Dec;71 Suppl 2(Suppl 2):ii16-9. doi: 10.1136/jnnp.71.suppl_2.ii16.
2
[Clinical evaluation of follow-up and disease course].[随访及疾病进程的临床评估]
Rev Neurol (Paris). 2001 Sep;157(8-9 Pt 2):1121-3.
3
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.多发性硬化继发进展期残疾进展的预后因素
J Neurol Sci. 2003 Feb 15;206(2):135-7. doi: 10.1016/s0022-510x(02)00426-4.
4
Multiple sclerosis: predicting risk and delaying progression.多发性硬化症：预测风险与延缓进展
Lancet Neurol. 2010 Jan;9(1):7-9. doi: 10.1016/S1474-4422(09)70336-9.
5
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.原发进展型与复发缓解型多发性硬化症：脑脊液寡克隆 IgM 的存在及其预后价值。
Mult Scler. 2011 Mar;17(3):303-11. doi: 10.1177/1352458510386996. Epub 2010 Nov 15.
6
The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis.多发性硬化症的自然史：一项基于地理区域的研究：8：家族性多发性硬化症
Brain. 2000 Mar;123 Pt 3:641-9. doi: 10.1093/brain/123.3.641.
7
MRI lesion loads and disability relationships in MS: more similar than different?多发性硬化症中MRI病灶负荷与残疾的关系：相似之处多于不同之处？
Neurology. 2009 Nov 10;73(19):1524-5. doi: 10.1212/WNL.0b013e3181c2f091. Epub 2009 Oct 14.
8
Primary progressive multiple sclerosis: progress and challenges.原发性进行性多发性硬化症：进展与挑战。
J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1100-6. doi: 10.1136/jnnp-2012-304140. Epub 2013 Feb 16.
9
[Multiple sclerosis: spontaneous course, natural history].
Rev Neurol (Paris). 2001 Sep;157(8-9 Pt 1):753-6.
10
[New immunomodulator for multiple sclerosis patients. 30% fewer relapse rates].
MMW Fortschr Med. 2002 May 6;Suppl 2:88.
引用本文的文献
1
NEDA-state, psychological symptoms and quality of life are stable in natalizumab-treated multiple sclerosis patients: An up to 6-years long follow-up study.那他珠单抗治疗的多发性硬化症患者的无疾病活动状态、心理症状和生活质量稳定：一项长达6年的随访研究。
Heliyon. 2024 Oct 18;10(20):e39536. doi: 10.1016/j.heliyon.2024.e39536. eCollection 2024 Oct 30.
2
The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis.磁共振成像测量对继发进展型多发性硬化症预测的不断演变的贡献。
J Neurol Neurosurg Psychiatry. 2024 Jul 22;96(3):231-8. doi: 10.1136/jnnp-2024-333917.
3
Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression.复发缓解型多发性硬化症患者的长期残疾结局：临床和人口统计学因素对疾病进展的影响
J Clin Med. 2024 Mar 21;13(6):1813. doi: 10.3390/jcm13061813.
4
Roles of astrocytes in response to aging, Alzheimer's disease and multiple sclerosis.星形胶质细胞在衰老、阿尔茨海默病和多发性硬化症中的作用。
Brain Res. 2021 Aug 1;1764:147464. doi: 10.1016/j.brainres.2021.147464. Epub 2021 Apr 1.
5
Application of Disease Etiology and Natural History to Prevention in Primary Health Care: A Discourse.疾病病因学和自然史在初级卫生保健预防中的应用：论述。
Med Princ Pract. 2020;29(6):501-513. doi: 10.1159/000508718. Epub 2020 May 18.
6
Transcranial Magnetic Stimulation as a Potential Biomarker in Multiple Sclerosis: A Systematic Review with Recommendations for Future Research.经颅磁刺激作为多发性硬化症潜在生物标志物的系统评价：对未来研究的建议
Neural Plast. 2019 Sep 16;2019:6430596. doi: 10.1155/2019/6430596. eCollection 2019.
7
Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.克拉屈滨片治疗荷兰复发性缓解型多发性硬化症的成本效果分析。
Appl Health Econ Health Policy. 2019 Dec;17(6):857-873. doi: 10.1007/s40258-019-00500-8.
8
Sexual dysfunction in female patients with relapsing-remitting multiple sclerosis.女性复发缓解型多发性硬化症患者的性功能障碍。
Brain Behav. 2017 Apr 14;7(6):e00699. doi: 10.1002/brb3.699. eCollection 2017 Jun.
9
Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.TnP的多种功能治疗作用：一种源自鱼毒的小的稳定合成肽在多发性硬化症小鼠模型中的作用
PLoS One. 2017 Feb 24;12(2):e0171796. doi: 10.1371/journal.pone.0171796. eCollection 2017.
10
Decision making in MS: factors affecting engagement in treatment choices.多发性硬化症中的决策制定：影响治疗选择参与度的因素
Funct Neurol. 2016 Jan-Mar;31(1):5-6. doi: 10.11138/fneur/2016.31.1.005.
本文引用的文献
1
Relapses and progression of disability in multiple sclerosis.多发性硬化症的复发与残疾进展
N Engl J Med. 2000 Nov 16;343(20):1430-8. doi: 10.1056/NEJM200011163432001.
2
Diagnostic brain MRI findings in primary progressive multiple sclerosis.原发性进行性多发性硬化症的脑部MRI诊断结果
Mult Scler. 2000 Apr;6(2):81-5. doi: 10.1177/135245850000600205.
3
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.多发性硬化症的自然史：一项基于地域的研究。5. 原发性进行性多发性硬化症的临床特征及自然史。
Brain. 1999 Apr;122 ( Pt 4):625-39. doi: 10.1093/brain/122.4.625.
4
Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?干扰素治疗多发性硬化症：它们能阻止疾病进展吗？
Arch Neurol. 1998 Dec;55(12):1578-80. doi: 10.1001/archneur.55.12.1578.
5
Primary progressive multiple sclerosis.原发性进行性多发性硬化症
Brain. 1997 Jun;120 ( Pt 6):1085-96. doi: 10.1093/brain/120.6.1085.
6
The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.盲法对一项随机、安慰剂对照的多发性硬化症临床试验结果的影响。
Neurology. 1994 Jan;44(1):16-20. doi: 10.1212/wnl.44.1.16.
7
On the pathogenesis of multiple sclerosis. A revised model of the cause(s) of multiple sclerosis, especially based on epidemiological data.
Clin Neurol Neurosurg. 1994 May;96(2):135-42. doi: 10.1016/0303-8467(94)90047-7.
8
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.多发性硬化症的自然史：一项基于地域的研究。I. 临床病程与残疾情况
Brain. 1989 Feb;112 ( Pt 1):133-46. doi: 10.1093/brain/112.1.133.
9
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.
Brain. 1989 Dec;112 ( Pt 6):1419-28. doi: 10.1093/brain/112.6.1419.
10
The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.
Brain. 1991 Apr;114 ( Pt 2):1057-67. doi: 10.1093/brain/114.2.1057.
Zotero 插件